The GNRH1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the GNRH1 gene has been disrupted to ablate expression of the gonadotropin-releasing hormone 1 precursor. This loss-of-function model is generated via multiplexed guide RNA targeting to effectively eliminate production of the GnRH decapeptide, providing a reliable tool for dissecting autocrine/paracrine GnRH functions in a colorectal adenocarcinoma context. The polyclonal nature of this product ensures representation of diverse editing events across the population, enabling robust functional comparisons with wild-type HT29 controls.
HT29 cells, the host line for this knockout product, were originally isolated from a colon adenocarcinoma of a 44-year-old Caucasian female and constitute a well-characterized epithelial model in colorectal cancer research. Under standard culture conditions, HT29 cells display an undifferentiated phenotype, yet they retain the capacity for mucin secretion and enterocytic differentiation upon appropriate stimulation, making them invaluable for studies of tumor cell plasticity, drug resistance, and epithelial?Cmesenchymal transition. Their widespread use in cancer biology is supported by a wealth of genomic, transcriptomic, and pharmacological data, facilitating integrative analyses when combined with targeted gene perturbations.
The GNRH1 gene product is processed by prohormone convertases to yield the active decapeptide GnRH, which engages the GNRHR, a G protein?Ccoupled receptor. This interaction classically triggers Gq/11-dependent activation of phospholipase C??, leading to IP3-mediated calcium mobilization and diacylglycerol-dependent protein kinase C (PKC) activation. Downstream, PKC can initiate the RAF?CMEK?CERK1/2 phosphorylation cascade, culminating in the activation of transcription factors such as ELK1, SRF, and EGR1. In extrapituitary tissues, GnRH signaling additionally connects to PI3K/AKT and calcium/calmodulin-dependent pathways. Key upstream regulators of GNRH1 include KISS1, estrogen, glucocorticoids, and TGF-??, whereas downstream effectors comprise immediate-early genes (FOS, JUN), matrix metalloproteinases (MMPs), and cyclin D1 (CCND1). Interacting partners such as G proteins (GNAQ/GNA11), ??-arrestins, and calmodulin further modulate signal duration and specificity.
In the colorectal adenocarcinoma setting, GNRH1 knockout profoundly disrupts the autocrine/paracrine GnRH signaling loop, eliminating ligand-induced GNRHR stimulation and thereby attenuating multiple pro-tumorigenic cascades. The absence of GnRH peptide curtails calcium flux, PKC-driven phosphorylation, and ERK1/2 activation, directly altering the transcriptional output of EGR1, FOS, and downstream target genes that govern cell cycle progression, apoptosis resistance, and migratory capacity. Consequently, this knockout model serves as a powerful platform to delineate the non-reproductive roles of GnRH in colon cancer biology, particularly its contributions to proliferation and invasive behavior, and to clarify the molecular basis of differential responses to GnRH analogs in tumor cells.
This polyclonal knockout cell population is ideally suited for a wide array of functional assays. Researchers can employ Western blotting to monitor phospho-ERK1/2 and phospho-PKC levels, RT-qPCR for expression analysis of EGR1, FOS, and other downstream targets, and ELISA to confirm absence of secreted GnRH. Functional studies including MTT or BrdU proliferation assays, Annexin V/PI apoptosis analysis, and Transwell migration assays directly interrogate phenotypic consequences of GNRH1 disruption. Additional applications encompass luciferase reporter assays driven by EGR1 promoters, phospho-kinase array profiling, and RNA-seq to delineate global transcriptomic changes. The model further supports drug resistance investigations and biomarker discovery efforts in colorectal cancer. For detailed technical specifications, lot-specific validation data, or ordering assistance, please contact Ascent Research.
